Medtronic/$MDT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Ticker
$MDT
Sector
Primary listing
NYSE
Employees
95,000
Headquarters
Galway, Ireland
Website
Medtronic Metrics
BasicAdvanced
$121B
26.01
$3.62
0.79
$2.81
3.02%
Price and volume
Market cap
$121B
Beta
0.79
52-week high
$96.25
52-week low
$79.29
Average daily volume
7M
Dividend rate
$2.81
Financial strength
Current ratio
2.014
Quick ratio
1.248
Long term debt to equity
54.389
Total debt to equity
61.393
Dividend payout ratio (TTM)
77.27%
Interest coverage (TTM)
8.95%
Profitability
EBITDA (TTM)
9,446
Gross margin (TTM)
65.38%
Net profit margin (TTM)
13.63%
Operating margin (TTM)
19.31%
Effective tax rate (TTM)
17.15%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
4.57%
Return on equity (TTM)
9.74%
Valuation
Price to earnings (TTM)
26.014
Price to revenue (TTM)
3.533
Price to book
2.52
Price to tangible book (TTM)
-22.44
Price to free cash flow (TTM)
22.782
Free cash flow yield (TTM)
4.39%
Free cash flow per share (TTM)
4.134
Dividend yield (TTM)
2.98%
Forward dividend yield
3.02%
Growth
Revenue change (TTM)
4.98%
Earnings per share change (TTM)
21.95%
3-year revenue growth (CAGR)
3.25%
10-year revenue growth (CAGR)
3.99%
3-year earnings per share growth (CAGR)
-2.24%
10-year earnings per share growth (CAGR)
5.35%
3-year dividend per share growth (CAGR)
3.02%
10-year dividend per share growth (CAGR)
8.05%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Bulls say / Bears say
Medtronic received CE Mark approval for its Visualase MRI-Guided Laser Ablation System, enabling a European launch that expands its neurosurgery portfolio (Reuters)
Medtronic secured a $337 million investment from Blackstone Life Sciences to fund four diabetes R&D programs, accelerating its development pipeline for next-generation diabetes technologies (Reuters)
In Q3 FY25, Medtronic’s diabetes segment grew 8.4%, while its cardiovascular and neuroscience segments rose 3.7% and 4.4% respectively, underpinning mid-single-digit organic revenue growth (Reuters)
Q3 medical-surgical revenue declined 1.9% to $2.07 billion, missing estimates as U.S. distributors destocked and surgical stapler competition intensified (Reuters)
Despite beating profit estimates, shares fell nearly 5% in premarket trading after Q3 results, underscoring the stock's sensitivity to operational setbacks (Reuters)
Medtronic is evaluating changes to its global manufacturing footprint in response to potential U.S. tariffs on imports from Mexico and Canada, introducing cost and supply-chain uncertainty (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Medtronic News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept26
Medtronic
DividendEx-dividend
Oct17
Medtronic
DividendPayment
$0.71Per share
FAQs
What’s the current market cap for Medtronic stock?
Medtronic (MDT) has a market cap of $121B as of September 18, 2025.
What is the P/E ratio for Medtronic stock?
The price to earnings (P/E) ratio for Medtronic (MDT) stock is 26.01 as of September 18, 2025.
Does Medtronic stock pay dividends?
Yes, the Medtronic (MDT) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $2.81 and the yield is 3.02%. Medtronic has a payout ratio of 77.27% on a trailing twelve-month basis.
When is the next Medtronic dividend payment date?
The next Medtronic (MDT) dividend payment is scheduled for October 17, 2025.
What is the beta indicator for Medtronic?
Medtronic (MDT) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.